Table 1.
Healthy control | lgAVN | lgAV without nephritis | p | |
---|---|---|---|---|
Subjects, n | 76 | 43 | 66 | |
Demographics | ||||
Age | 7.88 ± 3.024 | 9.42 ± 4.32 | 8.79 ± 4.04 | >0.05 |
Gender (male/female) | 44/32 | 26/17 | 37/29 | >0.05 |
Lipid profiles | ||||
TG (mmol/L) | 2.75 (1.12-3.39)b | 1.26 (0.8-1.66)a | 1.08 (0.67-1.87)a | <0.05 |
TC (mmol/L) | 0.84 (0.59-2.99)b | 3.93 (3.44-4.56)a | 3.98 (3.19-4.85)a | <0.05 |
HDL-C (mmol/L) | 1.23 (1.05-1.37) | 1.21 (1-1.36) | 1.29 (1.03-1.55) | >0.05 |
LDL-C (mmol/L) | 1.9 (1.5-2.16)b | 2.21 (1.77-2.75)a | 2.1 (1.57-2.78)a | <0.05 |
apoA (g/L) | 1.06 (0.99-1.15)b | 0.9 (0.75-1.04)a | 0.93 (0.78-1.06)a | <0.05 |
apoB (g/L) | 0.57 (0.47-0.66) | 0.58 (0.49-0.7) | 0.58 (0.45-0.72) | >0.05 |
apoM (mg/L) | 18.17 (15.83-20.22)a | 23.92 (21.25-26.1)b | 25.96 (23.50-27.46)c | <0.05 |
Kidney biochemical profiles | ||||
BUN (μmol/L) | 3.8 (3.25-4.47) | 4.02 (2.86-5.5) | 4.09 (2.99-4.95) | >0.05 |
CRE (μmol/L) | 30.9 (24.23-36.4)a | 41.1 (36-53)b | 35.55 (30.75-42.43)c | <0.05 |
UA (g/L) | 230.05 (181.93-269.63)a | 265 (218.6-330.3)b | 223.3 (187.13-281.55)a | <0.05 |
hs-CRP (mg/L) | / | 1.94 (1.02-3.87) | 3.74 (1.37-12.1) | <0.05 |
Immunoglobulins | ||||
lgG (g/L) | / | 8.4 (6.16-11) | 9.97 (8.29-11.7) | <0.05 |
lgM (g/L) | / | 2 (154-2.35) | 2.2 (1.52-3.19) | >0.05 |
lgA (g/L) | / | 1.25 (0.84-1.42) | 1.05 (0.87-1.56) | >0.05 |
lgE (g/L) | / | 150.8 (59.09-447.3) | 275.05 (119.38-298.63) | >0.05 |
Complements | ||||
C3 (g/L) | / | 0.95 (0.8-1.13) | 1 (0.9-1.15) | >0.05 |
C4 (g/L) | / | 0.18 (0.15-0.23) | 0.23 (0.18-0.28) | <0.05 |
abc means not sharing a common superscript are significantly different among the healthy controls, lgAVN, and lgAV without nephritis groups at p < 0.05. Data are presented as median (range). TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; apoA1: apolipoprotein A1; apoB: apolipoprotein B; apoM: apolipoprotein M.